Search

A recent study from Weill Cornell Medicine in New York City highlights the challenges of pharmacologic management of heart failure with preserved ejection fraction (HFpEF) in older adults. The research emphasizes the importance of considering age-related changes in medication effects, geriatric conditions, and individual health goals when treating older patients with HFpEF. Key considerations include the use of specific medications and the need for personalized care plans aligned with the patient's overall well-being. This peer-reviewed study provides valuable insights for healthcare professionals working with older adults with cardiovascular disease. [Extracted from the article]

Researchers at the University of Maryland conducted a study on the impact of angiotensin receptors on physical performance in older mice. The study found that mice lacking the Angiotensin Type 2 (AT2) receptor had higher body weight and poor aerobic performance compared to wild type mice. This research suggests that modifications in angiotensin receptors can affect physical performance in aging organisms. For more information, the full article can be accessed through Innovation in Aging. [Extracted from the article]

Researchers at the University of California San Diego (UCSD) conducted a study to assess the impact of Angiotensin-converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs) on amputation-free survival in patients with chronic limb-threatening ischemia (CLTI) undergoing peripheral vascular intervention (PVI). The study included 34,284 patients, with 46.3% discharged on ACEIs/ARBs. Patients on ACEIs/ARBs showed higher 1-year survival rates, freedom from amputation, and amputation-free survival compared to those not on these medications. The research suggests that ACEIs/ARBs are associated with improved outcomes in patients with CLTI undergoing PVI. [Extracted from the article]

Researchers at Kagawa University have published new studies on the potential renoprotective effects of angiotensin receptor-neprilysin inhibitors (ARNIs) in cardiorenal syndrome. The research highlights the dual action of ARNIs on the renin-angiotensin system and the natriuretic peptide system, particularly focusing on the impact of sacubitril/valsartan on kidney function in patients with CRS. The findings suggest that ARNIs may play a significant role in enhancing renal protection in individuals with cardiorenal syndrome, based on both pre-clinical and clinical studies. For more information, readers can access the full article in Frontiers in Medicine. [Extracted from the article]

A recent study conducted by researchers at the University of Chester focused on the effectiveness of combining angiotensin receptor blockers (ARBs) and hydrochlorothiazide (HCTZ) versus ARB monotherapy in controlling hypertension among adult patients. The study, which included seven randomized control trials involving 4814 participants, found that the ARB/HCTZ combination therapy resulted in a higher rate of achieving target blood pressure compared to ARB monotherapy, with no significant adverse effects reported. The researchers recommend health workers consider recommending ARB/HCTZ combination therapy for patients with uncontrolled hypertension. [Extracted from the article]

Researchers from the University of Arkansas for Medical Sciences have highlighted the ongoing public health issue of hypertension, a condition characterized by elevated blood pressure. The study emphasizes the significant burden of hypertension on cardiovascular health and mortality rates, attributing factors such as genetics, lifestyle, and stress to its prevalence. While lifestyle changes have shown limited success, the study suggests exploring new approaches, including digital health tools and compounds that target specific receptors, to better manage and treat hypertension. [Extracted from the article]

The University of Kufa conducted research on diabetic cardiomyopathy (DCM), a complication of diabetes mellitus that contributes to heart failure. The study highlighted the lack of targeted therapies for DCM and emphasized the importance of ongoing research into novel treatment strategies. The research focused on antioxidant therapies as a promising approach to limit DCM progression and improve cardiac function in diabetes-induced cardiomyopathy. The findings suggest the need for new therapeutic strategies and early detection methods for managing DCM effectively. [Extracted from the article]

A recent study conducted by researchers at the University of Barcelona examined the impact of chronic treatment with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) on short-term outcomes in patients with acute heart failure (AHF). The study, which included 17,920 patients diagnosed with AHF in Spanish Emergency Departments, found that patients receiving chronic ACEI/ARB treatment had better short-term outcomes, including lower in-hospital mortality rates and reduced need for hospital admission. The research concluded that chronic use of ACEI/ARB was associated with improved short-term outcomes for patients with AHF attending Emergency Departments. [Extracted from the article]

A study conducted by researchers at the University of California analyzed the prescribing patterns of Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in hospitalized patients with heart failure. The study found that the rates of ARNI prescription at discharge increased over a 7-year period, while the rates of Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Blocker (ARB) prescription decreased. The research suggests that there is room for improvement in ARNI prescription rates, with 55.4% of eligible patients receiving ARNI at the end of the study. [Extracted from the article]

A study conducted by the Chinese Academy of Sciences focused on the local structure of the angiotensin receptor-neprilysin inhibitor (S086) drug cocrystal using linear and nonlinear infrared spectroscopies. The research aimed to understand the active sites of the drug, S086, which is a combination of EXP3174 and sacubitril in a 1:1 molar ratio. The study revealed two forms of cocrystals of S086, xi-crystal, and alpha-crystal, with distinct structural variations in the binding state of multiple carboxyl anions to calcium ions. Linear and nonlinear IR spectroscopies were found to be effective in characterizing local crystal structures of drugs and identifying subtle differences between similar crystal structures. [Extracted from the article]

A recent study conducted at Robert Bosch Hospital focused on the efficacy of sparsentan in treating IgA nephropathy in patients already receiving SGLT2 inhibitors. The study involved 23 patients with stable kidney function and protein levels, showing a significant reduction in proteinuria after 14 weeks of sparsentan treatment. The research suggests that sparsentan may have a positive impact on proteinuria in patients with IgA nephropathy, even when used in combination with SGLT2 inhibitors. [Extracted from the article]

A recent systematic review conducted by researchers at the University Hospital of Ferrara in Italy focused on drug-based cardiovascular prevention in patients with Marfan Syndrome (MFS). The study found that beta-blockers are effective in slowing aortic enlargement, while angiotensin receptor blockers can be a useful alternative therapy to limit aortic growth. However, neither of these medications showed significant results on clinical aortic endpoints. The research highlighted the need for larger randomized clinical trials with adequate follow-up studies to establish the role of these treatments in MFS patients. [Extracted from the article]

Researchers at National Taiwan University conducted a study comparing the effectiveness of mineralocorticoid receptor antagonists (MRA) and renin-angiotensin system inhibitors/angiotensin receptor neprilysin inhibitors (RASI/ARNI) in heart failure with mildly reduced ejection fraction (HFmrEF). The study found that RASI/ARNI was associated with a lower risk of cardiovascular death compared to MRA, while MRA had a neutral effect on cardiovascular death and heart failure hospitalization. The research suggests that regular re-evaluation of heart failure treatment is essential for HFmrEF patients. [Extracted from the article]

A recent study conducted at Oregon Health & Science University (OHSU) explored the impact of Angiotensin-Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) on readmission rates following ileostomy creation. The research found that patients discharged with ACEI/ARB were at a higher risk for readmission within 30 days, suggesting that inhibition of the renin-angiotensin-aldosterone system (RAAS) may contribute to increased readmission rates. The study highlights the need for individualized care plans for patients with hypertension undergoing ileostomy creation to mitigate the risk of readmission. [Extracted from the article]

A recent study from Tongji University School of Medicine examined the impact of angiotensin-receptor neprilysin inhibitors on cardiovascular events and solute transport function in peritoneal dialysis patients. The study involved 102 patients, with those using ARNI showing improvements in blood pressure and left ventricular ejection fraction after 12 months of therapy. The research suggests that ARNI may have a protective role in reducing cardiovascular events and improving solute transport in peritoneal dialysis patients. [Extracted from the article]

A study conducted by researchers at the College of Pharmacy in Mosul, Iraq, focused on the effects of Angiotensin Receptor Blockers (ARBs) on apelin and visfatin in hypertension. ARBs target the renin-angiotensin system, which is crucial for cardiovascular health, controlling hypertension, fluid imbalance, and influencing adipose-derived hormones. The study highlighted the importance of understanding the relationship between ARBs, apelin, and visfatin to optimize therapeutic approaches for cardiovascular diseases. Researchers found that ARBs can influence the serum levels of apelin and visfatin, potentially enhancing their cardioprotective effects. [Extracted from the article]

A clinical trial, NCT06704633, is being conducted in rural Tanzania to evaluate the health status of patients with heart failure after switching from ACE inhibitors or ARBs to sacubitril-valsartan. The study aims to assess the benefits and safety of ARNI in African populations, focusing on symptomatic patients with reduced ejection fraction. The trial will recruit 238 participants at the St Francis Regional Referral Hospital in Ifakara over a 30-month period, with a hypothesis that health status will improve after the switch. The study will measure outcomes such as the Kansas City Cardiomyopathy Questionnaire summary score and 6-minute walking test. [Extracted from the article]

Researchers from Tongji University School of Medicine in Shanghai, China, conducted a study on the effects of LCZ696, an angiotensin receptor-neprilysin inhibitor, on peritoneal mesothelial cells and macrophage M2 polarization. The study found that LCZ696 improved peritoneal fibrosis and inhibited epithelial-mesenchymal transition in mice and human cells by blocking specific signaling pathways. The research also showed that LCZ696 inhibited M2 macrophage polarization by regulating the STAT6 pathway. This study provides insights into potential therapeutic interventions for peritoneal fibrosis and related conditions. [Extracted from the article]

A recent study conducted at People's Hospital examined the relationship between the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and the risk of developing ventilator-associated pneumonia (VAP) in patients receiving mechanical ventilation in the intensive care unit (ICU). The study, which included 8,888 patients, found that those on ACEI or ARB therapy had a lower risk of developing VAP. The research suggests that these medications may have a protective effect, especially in patients with specific comorbidities and those receiving vasopressors and antibiotics. [Extracted from the article]

Researchers at Peking University People's Hospital conducted a systematic review and meta-analysis on the efficacy of angiotensin receptor blockers (ARBs) for reducing nocturnal blood pressure in patients with mild to moderate hypertension. The study included 77 studies with 13,314 participants and found that allisartan, olmesartan, and telmisartan were associated with greater reductions in nocturnal systolic blood pressure. Allisartan was particularly effective in reducing nighttime blood pressure more than daytime blood pressure and improving the dipping pattern. This research highlights the importance of controlling nocturnal blood pressure for reducing cardiovascular risk in hypertensive patients. [Extracted from the article]

Researchers at the University of Montreal have conducted a study on the impact of neonatal hyperoxia on adult cardiac autonomic function in rats, focusing on the role of angiotensin II type 1 receptor activation. The study found that neonatal hyperoxia led to various changes in autonomic and cardiac sympathetic functions in adult rats, partly due to the activation of the renin-angiotensin system during the neonatal period. The research was supported by various organizations, including the Canadian Institutes of Health Research and the Heart & Stroke Foundation of Canada. The findings have been published in the European Journal of Pharmacology and are available for further exploration. [Extracted from the article]

Researchers at Yeungnam University conducted a study to compare the survival rates of patients undergoing hemodialysis who were prescribed angiotensin-converting enzyme inhibitors (ACEI) versus angiotensin II receptor blockers (ARB). The study found that patients receiving ACEI and ARB had comparable survival rates overall, but ARB was associated with better survival in patients with diabetes or heart disease, while ACEI showed better outcomes in young patients or those without diabetes or heart disease. The study was supported by various research programs in South Korea and was published in Renal Failure. [Extracted from the article]

Researchers from Semmelweis University in Budapest, Hungary, have conducted a study on the potentiation of NMDA receptors by AT1 angiotensin receptor activation in layer V pyramidal neurons of the rat prefrontal cortex. The study aimed to understand how angiotensin II impacts NMDA receptor activity in the brain. The findings suggest that the potentiation of NMDA currents by angiotensin II, involving AT1 receptor activation and dopaminergic signaling, may underlie the effects of the renin-angiotensin system on neuronal functions. This research provides valuable insights into the role of peptide receptors in cognitive functions and brain research. [Extracted from the article]

Researchers from Georgetown University have highlighted the frequent occurrence of bladder symptoms provoked by short, rapid-acting loop diuretics in patients with cardiovascular diseases, hypertension, congestive heart failure, and chronic kidney disease. These symptoms, including urinary urgency and frequency, can significantly impact quality of life and treatment adherence. The study suggests alternative diuretics or medications to mitigate these bladder-related side effects and improve patient outcomes. For more information, the full research article can be accessed in the American Journal of Hypertension. [Extracted from the article]

The article from Cardiovascular Week discusses new research from Duke University School of Medicine on hypertension, focusing on the role of podocytes in kidney damage and disease progression. Podocytes, specialized cells in the kidney, are affected by oxidative stress, leading to proteinuria and glomerulosclerosis in hypertensive nephropathy. The study highlights the importance of early detection of podocyte injury and albuminuria, as well as the need for targeted therapies to protect podocytes and preserve kidney function in hypertensive patients. The research emphasizes the complex interplay between oxidative stress, ion channel activation, and redox injury pathways in podocyte dysfunction. [Extracted from the article]

Researchers at the University of Colorado conducted a study called TRACK to investigate the management of hyperkalemia, a condition characterized by high levels of potassium in the blood. The study enrolled 1330 participants from multiple countries and aimed to understand healthcare providers' decision-making processes in managing hyperkalemia. The findings of this study will shed light on practitioners' approaches to hyperkalemia management and potentially improve patient outcomes. Financial support for the research was provided by AstraZeneca. [Extracted from the article]

A recent study conducted at the University of North Texas Health Science Center examined the adherence to a 36-hour washout period when transitioning patients from angiotensin-converting enzyme inhibitors (ACEi) to angiotensin receptor/neprilysin inhibitors (ARNI) for heart failure treatment. The study found that 67% of patients received the full washout period, with no significant differences in hospital readmissions or adverse effects between groups. The researchers suggest that larger, multicenter studies are needed to further explore prescribing practices in different settings and the role of pharmacists in ensuring adherence to recommended protocols. [Extracted from the article]

A recent study from Monash University explores the functional crosstalk between Angiotensin Receptors (Types 1 and 2) and Relaxin Family Peptide Receptor 1 (Rxfp1), shedding light on how these cell surface receptors interact and influence each other's actions. The research suggests that these receptors can function as homodimers and heterodimers, impacting the function of each receptor. The study focuses on the implications of this interaction for fibrosis, a condition characterized by tissue scarring resulting from failed wound healing, which is often associated with chronic diseases and organ dysfunction. The findings have been published in the British Journal of Pharmacology and are available for further exploration. [Extracted from the article]

A study conducted by researchers at Brown University explored the relationship between the use of Angiotensin Receptor Blockers (ARBs) and the prevalence of adhesive capsulitis in patients. The study, which analyzed data from a large national insurance database, found that patients prescribed ARBs had lower rates of newly diagnosed adhesive capsulitis and required less surgical intervention compared to a control group. The findings suggest a potential protective effect of ARBs against the development of adhesive capsulitis, although further investigations are needed to understand the underlying mechanisms. The research was published in the Journal of Shoulder and Elbow Surgery and has been peer-reviewed. [Extracted from the article]

A study conducted by researchers at Dokkyo Medical University in Tochigi, Japan, focused on the effects of sacubitril/valsartan, a combination drug that acts as a neprilysin inhibitor and angiotensin receptor blocker, on patients after cardiac surgery using cardiopulmonary bypass. The study involved 63 patients who underwent open heart surgery and were treated with sacubitril/valsartan, showing that the drug was safe and led to improvements in renal function and a reduction in postoperative atrial fibrillation. The research concluded that sacubitril/valsartan suppressed the activation of the renin-angiotensin-aldosterone system and increased serum atrial natriuretic peptide concentrations. [Extracted from the article]

A recent study conducted at the University of Gothenburg focused on the long-term continuation of pharmacological treatment for secondary prevention after a myocardial infarction (heart attack). The study, which followed individuals aged 18-84 years for up to 16 years, found that the utilization of guideline-recommended medical therapy decreased significantly after hospitalization for a heart attack. However, the research concluded that the use of certain medications, such as antiplatelets/anticoagulants, ACE inhibitors/angiotensin receptor blockers, and statins, reduced the risk of all-cause mortality and recurrent heart attacks. [Extracted from the article]

A recent study conducted at Lanzhou University in Gansu, China, explored the impact of using angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) on the survival of hypertensive patients with cancer. The study found that patients with certain types of cancer who used ACEIs or ARBs had significantly increased survival times, except for those with breast cancer and uroepithelial carcinoma. The research suggests that further investigation into the mechanisms of action of these drugs could lead to novel therapeutic options and improve the prognosis of cancer patients in the future. [Extracted from the article]

The article discusses the critical public health concern of heart failure with preserved ejection fraction (HFpEF), highlighting its high mortality and re-hospitalization rates. It emphasizes the complexity of HFpEF as a multi-organ systemic syndrome associated with various risk factors. The study focuses on investigating the role of gut microbiota and metabolites in HFpEF, recognizing the potential of targeting the gut microbiome as a novel therapeutic strategy for managing cardiovascular diseases. The clinical trial NCT06645535 aims to explore changes in gut microbiota and metabolites in HFpEF patients to provide insights into potential biomarkers and therapeutic targets for the condition. [Extracted from the article]

A clinical trial, NCT06655480, is being conducted to evaluate the efficacy of triple combination therapy (ARNI, SGLT2i, MRA) in patients with advanced heart failure with preserved ejection fraction (HFpEF). The trial aims to assess the impact of this therapy on clinical status, structural and functional cardiac parameters, and myocardial fibrosis over a 52-week period. The study is interventional, randomized, and open-label, with a primary focus on treatment. The trial is not yet recruiting participants, with an enrollment target of 50 individuals aged 40 to 80 years. The research is being led by the National Medical Research Center for Cardiology, Ministry of Health of the Russian Federation. [Extracted from the article]

A recent report from European University Cyprus highlights the importance of targeting sodium in heart failure (HF) treatment. The study emphasizes the role of sodium imbalance in HF progression and suggests interventions such as dietary sodium restriction and specific medications to improve outcomes. The research also discusses the use of advanced technologies like 23(Na+) magnetic resonance imaging (MRI) and wearable devices for monitoring tissue sodium levels in HF patients. Further studies are needed to explore the clinical implications of sodium storage and related mechanisms in HF morbidity and mortality. [Extracted from the article]

A study conducted at the University of Glasgow examined cognitive dysfunction in patients with heart failure and preserved ejection fraction. The research found that even mild cognitive impairment was associated with worse outcomes, including death. Patients with lower cognitive function scores had a higher risk of heart failure hospitalization, cardiovascular death, and all-cause death. The study highlights the importance of considering cognitive function in the management of heart failure patients. [Extracted from the article]

A recent study conducted by researchers at the Dana-Farber Cancer Institute in Boston, Massachusetts, explored the impact of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) prior to radical cystectomy (RC). The study found that ACEi intake was potentially associated with an increased pathologic complete response (pCR) in patients with MIBC receiving NAC before RC, particularly in patients with higher clinical stage disease and female sex. The research suggests that the renin-angiotensin system (RAS) may be a potential therapeutic target for aggressive MIBC. [Extracted from the article]

A recent study led by researchers at the University of California - Los Angeles highlights the life-saving impact of guideline-directed medical therapy (GDMT) in heart failure patients. The study found that many individuals with heart failure with reduced ejection fraction (HFrEF) did not receive the recommended treatment, indicating the challenges in implementing global guidelines. However, if GDMT is optimally implemented, it could prevent 1.2 million deaths per year worldwide, with significant potential lives saved in the Eastern Mediterranean, Southeast Asia, and Western Pacific regions. The study emphasizes the importance of addressing heart failure as a global health issue and the need for urgent therapeutic interventions. [Extracted from the article]

A recent study conducted at Stanford University examined the quality of care for heart failure patients across different demographic groups. The researchers found that there were disparities in guideline-based quality measures, which likely contributed to differences in outcomes. However, after adjusting for patient characteristics, there were no significant differences between men and women for most measures. Racial and ethnic minorities, as well as Medicaid/uninsured patients, had similar or better adjusted measure performance compared to White and Medicare/privately insured patients. There were within-hospital differences in the use of certain treatments for historically marginalized groups. Overall, the study concluded that while most measures of heart failure care were equitable, there were still variations across hospitals. [Extracted from the article]

A recent study conducted in Tianjin, People's Republic of China, compared the clinical outcomes of patients with unstable angina who underwent percutaneous coronary intervention (PCI) and received either angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) treatment. The study found that there were no significant differences in major adverse cardiovascular and cerebrovascular events, all-cause death, nonfatal myocardial infarction, stroke, and target vessel revascularization between the ACEI and ARB groups. The researchers concluded that the prognosis for patients with preserved left ventricular systolic function after PCI was comparable between ACEI and ARB treatment. This study was supported by the Tianjin Science and Technology Project and has been peer-reviewed. [Extracted from the article]

Researchers at Nanjing Medical University in China have conducted a study on peptide receptors and their potential role in immune checkpoint blockade (ICB) therapy. The study found that angiotensin II receptor 1 (AGTR1), a target of angiotensin receptor blockers (ARBs), is overexpressed in armored and cold tumors and is associated with a poor response to ICB therapy. The researchers also discovered that ARBs can suppress the aggressiveness of tumor cells with high AGTR1 expression and enhance the efficacy of ICB therapy. These findings provide new insights into the treatment of refractory armored and cold tumors. [Extracted from the article]

A recent study conducted by researchers at Xuzhou Medical University in China examined the safety and efficacy of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan in patients with end-stage renal disease (ESRD) undergoing dialysis. The study included 10 studies involving 649 patients and found that ARNI was associated with improvements in blood pressure and left ventricular function in ESRD patients. The treatment was generally well tolerated and showed greater benefits with early intervention. However, further prospective studies are needed to fully understand the long-term efficacy and safety of sacubitril/valsartan in dialysis patients. [Extracted from the article]

A recent study conducted at Minia University in Egypt has found that sacubitril/valsartan (Sac/Val) may be effective in alleviating sepsis-induced myocardial injury in rats. Sepsis is a life-threatening condition that can lead to cardiac dysfunction and injury. The researchers administered Sac/Val to rats with sepsis and observed improvements in cardiac enzymes, inflammation markers, and histopathological changes. The study suggests that Sac/Val has anti-inflammatory, antioxidant, and antiapoptotic properties that can protect against sepsis-induced cardiac damage. [Extracted from the article]

A recent study conducted by the University of Michigan has reported findings on glomerulosclerosis, a kidney disease. The study focuses on the phase 3 DUPLEX trial, which is evaluating the efficacy and safety of sparsentan, a new treatment for focal segmental glomerulosclerosis (FSGS). The trial includes 371 patients from various regions and racial backgrounds, with a median age of 42 years. The study aims to provide important insights into the treatment effect of sparsentan in a diverse FSGS population. The research was financially supported by Travere Therapeutics, Inc. [Extracted from the article]

A recent study conducted at Taichung Veterans General Hospital in Taiwan found that the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is associated with a reduced risk of poststroke epilepsy (PSE) in patients with ischemic stroke. The study, which used Taiwan's National Health Insurance Research Database, included 182,983 ACEI/ARB users and 38,365 nonusers. Nonusers exhibited a higher risk of PSE compared to ACEI/ARB users, and discontinued ACEI/ARB users showed the highest risk. The study suggests that continuing ACEI/ARB use after stroke is important, especially for younger patients. [Extracted from the article]

A recent study conducted at the Al Dabbous Cardiac Center in Kuwait examined the effectiveness and safety of angiotensin receptor-neprilysin inhibitor (ARNI) in treating heart failure with reduced ejection fraction (HFrEF) patients. The study included 114 adult patients who were treated with ARNI for 6 months. The results showed significant improvements in cardiac remodeling and clinical parameters, such as left ventricular ejection fraction, left ventricular end-diastolic diameter, and New York Heart Association Functional Classification. The study suggests that ARNI could be a valuable therapeutic option for HFrEF patients in the Middle East. Further research is needed to optimize its use and enhance patient outcomes. [Extracted from the article]

Researchers at North Dakota State University have conducted a study on the use of liposomes to reduce blood pressure through brain delivery of nanoparticles loaded with plasmid DNA encoding angiotensin receptor shRNA. The researchers synthesized dual-functionalized liposomes that were loaded with the plasmid DNA and demonstrated biocompatibility and efficient delivery to brain-derived cell lines. In experiments with spontaneously hypertensive rats, the treatment led to a significant decrease in blood pressure compared to saline-treated rats. This research provides promising insights into potential therapeutic approaches for neurogenic hypertension. [Extracted from the article]

Researchers from Aichi Medical University in Japan conducted a study to identify predictors of hypotension (low blood pressure) after administering angiotensin receptor-neprilysin inhibitors (ARNI) to patients with heart failure. The study analyzed data from 138 patients with heart failure who were treated with ARNI between August 2020 and July 2021. The researchers found that the presence of atrial fibrillation, a higher BUN/Cr ratio (blood urea nitrogen/creatinine ratio), and higher systolic blood pressure at baseline were significant independent predictors of hypotension after ARNI administration. The study highlights the need for caution when administering ARNI to patients with heart failure. [Extracted from the article]

Researchers at the University of Toyama in Japan have conducted a study on the use of vericiguat therapy in patients with systolic heart failure. Vericiguat is a soluble guanylate cyclase stimulator that has shown efficacy in treating heart failure. The study found that patients with higher baseline systolic blood pressure were more likely to benefit from vericiguat therapy. This research provides valuable insights into the specific subset of individuals who can benefit from this therapy. [Extracted from the article]